阅读说明：本技术 一种尿激酶的制备方法及其冻干粉 (Preparation method of urokinase and freeze-dried powder thereof ) 是由 李尔华 顾京 赵江峰 魏文培 于 2019-12-24 设计创作，主要内容包括：本发明涉及一种高纯度大分子尿激酶的制备方法及其冻干粉,属于生物化学工程技术领域。具体包括步骤：(1)制备尿激酶粗品；(2)制备尿激酶精品；(3)提纯；所述步骤(3)中将步骤(2)得到的尿激酶精品溶解后,将尿激酶精品溶液加入阳离子交换层析柱进行提纯；将提纯后的尿激酶进行冻干即得到尿激酶冻干粉。所述阳离子交换层析柱中充填的填料为Capto S impAct、SP sepharose HP、source 30S中的一种。本发明选择高分辨率离子交换层析,在保证纯度和活性收率的前提下,大大降低了生产成本,使得高纯度大分子量尿激酶的规模化生产成为可能。(The invention relates to a preparation method of high-purity macromolecular urokinase and freeze-dried powder thereof, belonging to the technical field of biochemical engineering. The method specifically comprises the following steps: (1) preparing a crude urokinase product; (2) preparing a fine urokinase product; (3) purifying; dissolving the urokinase refined product obtained in the step (2) in the step (3), and adding the urokinase refined product solution into a cation exchange chromatographic column for purification; and (3) freeze-drying the purified urokinase to obtain the urokinase freeze-dried powder. The filler filled in the cation exchange chromatographic column is one of Capto S impAct, SP sepharose HP and source 30S. The invention selects high-resolution ion exchange chromatography, greatly reduces the production cost on the premise of ensuring the purity and the activity yield, and makes the large-scale production of the high-purity macromolecular urokinase possible.)

1. A method for preparing urokinase, which is characterized in that: the method comprises the following steps:

(1) preparing a crude urokinase product; (2) preparing a fine urokinase product; (3) purifying;

dissolving the urokinase refined product obtained in the step (2) in the step (3), and adding the urokinase refined product solution into a cation exchange chromatographic column for purification;

the filler filled in the cation exchange chromatographic column is one of Capto S impAct, SP sepharose HP and source 30S.

2. The method of claim 1, wherein: when the urokinase refined solution is purified in a cation exchange chromatography column, the urokinase refined solution is firstly washed by an equilibrium buffer solution and then eluted by an elution buffer solution.

3. The method of claim 2, wherein: the equilibration buffer is selected from: one of acetate buffer, citrate buffer, phosphate buffer and Tris-HCl buffer; and the equilibration buffer contains 150-500mM sodium chloride.

4. The method of claim 2, wherein: the elution buffer was an acetate buffer containing 500-.

5. The method of claim 1, wherein: and (4) before purification in the step (3), adjusting the conductivity of the fine urokinase solution to be 15-90 ms/cm.

6. The method of claim 1, wherein: and (3) before purification in the step (3), adjusting the pH value of the urokinase refined solution to 4.5-7.5.

7. The method of claim 1, wherein: the step (1) comprises the following steps: firstly, adding fresh male urine into silica gel for adsorption, loading the silica gel into a column, washing the column by using tap water, eluting the column by using ammonia water, and collecting eluent; then adding the eluent into solid ammonium sulfate for precipitation, filtering, and collecting filter residue, namely the crude urokinase.

8. The method of claim 1, wherein: the step (2) comprises the following steps: dissolving and filtering the crude urokinase to obtain a fine urokinase product.

9. A urokinase freeze-dried powder is characterized in that: the urokinase lyophilized powder is obtained by lyophilizing urokinase obtained by the preparation method of any one of claims 1-8.

10. The urokinase lyophilized powder of claim 9, wherein: the content of macromolecular urokinase in the urokinase freeze-dried powder is not less than 95%.

Technical Field

The invention belongs to the technical field of biochemical engineering, and particularly relates to a preparation method of urokinase and freeze-dried powder thereof.

Background

Urokinase is a thrombolytic drug extracted from fresh human urine, which can activate plasminogen to convert into active plasmin, which can convert insoluble fibrin into soluble peptides, thereby dissolving thrombus. Therefore, it is clinically used for treating thrombosis, thromboembolism and other diseases. When urokinase is combined with an anticancer agent, the urokinase can dissolve fibrin around cancer cells, so that the anticancer agent can penetrate into the cancer cells more effectively, thereby improving the capability of the anticancer agent in killing the cancer cells. Therefore, urokinase is also a good cancer adjuvant, and it has no problem of antigenicity and can be used for a long time.

Urokinase is a serine protease produced by human renal tubular epithelial cells, is an alkaline protein, has an isoelectric point of about pH8.7, is white amorphous powder, and is easily soluble in water; the dilute solution is unstable in property, needs to be used fresh, and needs not to be diluted by an acid solution, and the freeze-dried state can be stable for years. Urokinase is proteolytic enzyme with strong specificity, the activity of synthetic substrate is similar to that of trypsin and plasmin, and it also has esterase activity, non-antigenicity, does not produce antibody in vivo, and its half-life in vivo is (14 +/-6) min.

Urokinase mainly comprises macromolecular urokinase (H-UK) with molecular weight of 54000 and small urokinase (L-UK) with molecular weight of 34000, wherein the former is naturally occurring form, and the latter is degradation product of H-UK. Both UK have biological activity, but enzyme kinetic tests and clinics carried out in vitro show that H-UK is more effective and has lower side effect than L-UK, so that urokinase products clinically used at present have strict requirements on controlling the content of small molecular weight urokinase.

Since the 70 s in the 20 th century, the preparation of high-purity large-molecular-weight urokinase has been on the rise, and many refining methods have been reported, but most methods have the problems of low recovery rate, poor economic benefit and no mass production.

In chinese patent application CN105238772A (a urokinase separation and purification method), urokinase is separated and purified to obtain a urokinase solution with endotoxin removed, specifically, male urine is acidified, adsorbed by a column of celite, then eluted with ammonia water and a sodium chloride solution, and then the eluate is salted out to obtain a crude urokinase product, and then the crude urokinase product is added to ammonia water for dissociation to obtain a urokinase solution; in the purification process, the urokinase solution is eluted through a gel column filled with gel fillers such as cellulose, ion exchange resin and the like, and the product is obtained. However, this method cannot achieve separation of large-molecule urokinase and small-molecule urokinase. The chinese patent application CN101701215A (a method for preparing urokinase) combines a D160 cation resin exchange method, an affinity membrane chromatography and an affinity chromatography, starting with a crude urokinase product to prepare urokinase, the final specific activity of the obtained urokinase can reach more than 15 ten thousand IU/mg.pr, the relative content of the high molecular urokinase can reach more than 96%, however, the yield of the biological activity is only 65%, so that the actual clinical requirements at the current stage cannot be met, and meanwhile, the affinity membrane chromatography used in the method has high production cost, and large-scale production cannot be performed. In the chinese patent application CN106929497A (a method for separating and purifying urokinase), a crude urokinase product is dissolved and then added to a dextran microsphere column or an agarose microsphere column for purification, and finally the specific activity of urokinase can be increased to more than 2 ten thousand IU/mg protein, and the yield of the obtained urokinase is 75-87%.

Disclosure of Invention

The technical problems to be solved by the invention are that the production cost is high in the urokinase production and purification method in the prior art, and the obtained urokinase with large molecular weight cannot be ensured to have high purity, high activity yield and the like.

In order to solve the technical problems, the invention provides a preparation method of urokinase, which comprises the following steps:

(1) preparing a crude urokinase product; (2) preparing a fine urokinase product; (3) purifying;

dissolving the urokinase refined product obtained in the step (2) in the step (3), and adding the urokinase refined product solution into a cation exchange chromatographic column for purification; water can be used as solvent to dissolve fine urokinase.

The filler filled in the cation exchange chromatographic column is high-resolution ion chromatographic filler, and can be selected from one of Capto SimPopt, SP sepharose HP and source 30S.

Further, when the urokinase refined solution is purified in the cation exchange chromatography column, the solution is firstly washed by the balance buffer solution, and when the solution UV280nm after washing the chromatography column by the balance buffer solution is less than 0.1, the solution is eluted by the elution buffer solution.

Further, the equilibration buffer is selected from: one of acetate buffer, citrate buffer, phosphate buffer and Tris-HCl buffer; and the equilibration buffer contains 150-500mM sodium chloride.

Further, the elution buffer was an acetate buffer containing 500-1000mM sodium chloride.

The equilibrium buffer solution with lower sodium chloride content can elute the small-molecule urokinase in advance, and then the elution buffer solution with higher sodium chloride content is used for eluting the large-molecule urokinase in the chromatographic column, thereby realizing the separation and purification of the large-molecule urokinase and the small-molecule urokinase.

Further, before the purification in the step (3), the conductivity of the urokinase refined solution is adjusted to be 15-90 ms/cm. The method comprises the steps of adjusting the conductivity of a urokinase refined solution by using an equilibrium buffer solution, specifically adding the equilibrium buffer solution into the urokinase refined solution, loading the mixed solution onto a column after the conductivity meets the requirement, and then eluting the column by using the equilibrium buffer solution and an elution buffer solution in sequence.

Further, before the purification in the step (3), adjusting the pH value of the urokinase refined solution to 4.5-7.5; further, the pH is 4.5-6.5.

Further, the step (1) comprises the steps of: firstly, adding fresh male urine into silica gel for adsorption, loading the silica gel into a column, washing the column by using tap water, eluting the column by using ammonia water, and collecting eluent; then adding the eluent into solid ammonium sulfate for precipitation, filtering, and collecting filter residue, namely the crude urokinase. The precipitation temperature is 0-10 deg.C, and further 4-8 deg.C when precipitating in solid ammonium sulfate.

Further, the step (2) comprises the steps of: dissolving and filtering the crude urokinase to obtain a fine urokinase product.

The invention also claims urokinase freeze-dried powder, wherein the urokinase freeze-dried powder is obtained by freeze-drying urokinase obtained by the preparation method.

Furthermore, in the urokinase freeze-dried powder, the content of macromolecular urokinase is not less than 95%, and the activity yield of macromolecular urokinase is not less than 90%.

On the basis of the existing urokinase production process, the invention adopts high-resolution cation exchange chromatography and combines the optimization of other process conditions to prepare the high-purity macromolecular urokinase product with the macromolecular urokinase content of not less than 95 percent, namely the small-molecular urokinase content of less than 5 percent. The principle of the invention is that according to the difference of molecular weight and the weak difference of charged charge of the urokinase with different sizes, the urokinase is obtained by the methods of ion exchange and gradient elution: in the purification process, firstly, the high-resolution cation exchange chromatography column is washed by adding an equilibrium buffer solution with the sodium chloride content of 150-.

The high-purity macromolecular urokinase has smaller side effect in clinical use, and simultaneously, the yield is ensured (the activity recovery rate is more than 90 percent), so that the economic benefit of manufacturers can be effectively ensured.

The invention adopts high-resolution ion chromatographic packing, in particular to Capto S impAct, SP sepharose HP or source30S, which are purchased from GE company in America, realizes the effective separation of macromolecular urokinase and small-molecular urokinase by optimizing various process parameters such as balance buffer formula, elution method, pH, conductivity and the like, and adopts a freeze-drying process to obtain a urokinase freeze-dried powder product with the macromolecular urokinase content being equal to or greater than 95% and the activity yield being greater than 90%, thereby meeting the requirement of mass production economic benefit.

Urokinase is widely used clinically as a protein drug extracted from fresh male urine. In order to ensure the curative effect and reduce the side effect, the finished product of human urokinase has strict control requirements on the content of small molecular weight urokinase. Gel chromatography is frequently used in the reported methods for purifying urokinase, which can meet the requirements of purity and yield of macromolecular urokinase, but the production cost is high, so that large-scale production cannot be carried out. The invention selects high-resolution ion exchange chromatography, greatly reduces the production cost on the premise of ensuring the purity and the activity yield, and makes the large-scale production of the high-purity macromolecular urokinase possible.

Compared with the prior art, the preparation method of urokinase has the following advantages:

(1) the invention uses high resolution cation chromatographic packing as chromatographic column packing, and uses the balance buffer solution to wash firstly, and elutes the micromolecule urokinase, then uses the elution buffer solution to wash the column, and can wash and remove the macromolecule urokinase, and realizes the separation and purification of the micromolecule urokinase for the first time.

(2) The urokinase freeze-dried powder product prepared by the urokinase preparation method has high macromolecular urokinase content, high activity yield and better clinical use effect.

(3) The preparation method of urokinase is an improvement on the basis of the existing production process, and a new production line does not need to be rebuilt.

(4) The preparation method of urokinase is simple and can realize industrial mass production.

Drawings

FIG. 1: SDS-PAGE of the urokinase product obtained in example 1.

FIG. 2: SDS-PAGE of the urokinase product obtained in example 2.

Detailed Description

The technical scheme of the invention is explained in detail through the figures and the specific embodiments of the specification.